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Background: The rationale for this trial was based on the results of a 
meta analysis on PCI in SCLC complete responders, which showed a 
signiﬁcant trend towards a reduction of the brain metastasis (BM) rate 
among patients who received higher PCI doses. This suggested that it 
was important to determine if higher dose PCI could further decrease 
the risk of brain metastases. This is the ﬁrst trial evaluating the optimal 
dose for PCI not only in terms of efﬁcacy but also quality of life. 
Methods: From September 1999 to December 2005, 720 patients with 
limited SCLC in complete remission were randomised: 360 patients 
to a standard PCI dose (25 Gy/10 fractions/12 days), 360 patients to a 
higher PCI dose (36 Gy) with conventional administration for 78% pts 
(36 Gy/18 fractions) or accelerated hyperfractionated administration for 
22% (36 Gy/24 twice-daily fractions). Every center had to opt for one 
of the high dose PCI schemes before including the ﬁrst patient, except 
in the RTOG where patients were randomised between conventional or 
accelerated hyperfractionated radiotherapy. The main endpoint is the 
incidence of brain metastasis. Besides overall survival, the secondary 
end-points are quality of life (QlQBM20) and possible clinical and 
radiological late sequelae (Lentsoma scale) assessed yearly.
Results: Median age was 60 years, 64% of patients were male. All 
patients had a baseline brain imaging. The baseline QlQBM20 and 
Lentsoma were available for 94% of patients:10 to 20% of patients had 
minor subjective signs before receiving PCI (table). Compliance to 
treatment was good: 94% received the allocated PCI dose. Only 9 pa-
tients never received PCI. 17 patients had however a deﬁnite PCI inter-
ruption (death for 2 patients, toxicity for 2, progression for 1 and minor 
reasons for 12). 49% of patients had some immediate toxicity (table). 
4 adverse events possibly related to PCI were observed (1 death, 1 
generalized seizure and 1 transient ischemic attack in the conventional 
arm and 1 death in the high dose arm).
Conclusion: In this large scale phase III trial, PCI compliance was 
good. Immediate toxicity was equivalent in the standard and the high 
dose arms. At baseline, 10 to 20% patients showed minor abnormalities 
described both by physicians and reported by the patients in the quality 
of life forms. Updated data on efﬁcacy and toxicity will be analysed in 
2008.
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Background: In a Japanese randomized trial, treatment with 
irinotecan+cisplatin in patients with SCLC-ED was associated with 
prolonged survival as compared to etoposide+cisplatin. The present 
trial was undertaken to evaluate the effects of irinotecan+carboplatin 
compared to etoposide+carboplatin.
Patients and Methods: Patients with SCLC-ED were randomized 
to receive either etoposide, 120 mg/m2/day, orally, on days 1-5, plus 
carboplatin, AUC=4 (Chatelut formula) on day 1 (EC), or irinotecan, 
175 mg/m2, plus carboplatin (Chatelut AUC=4), both on day 1 (IC). 
Treatments were repeated every 3 weeks, with 4 cycles planned. 
Primary endpoint was overall survival (OS), secondary were quality 
of life (QoL) evaluated by EORTC-QLQ-C30/LC13, and frequency of 
complete remissions (CR). No upper age nor performance status limits 
were applied.
Results: Between November, 2001 and July, 2005, 220 patients 
were randomized. 210 were eligible (EC 105, IC 105), while 10 were 
excluded due to wrong diagnosis (8), limited disease (1) or elevated 
liver enzymes (1). WHO performance status was: PS0: 20, PS1: 91, 
PS2: 62, PS3: 29, and PS4: 8 patients. Median age was 67 years (range 
39-82). By 1st August, 2006, 192 patients had died (EC 100, IC 92). 
Median OS was 214 days in the EC group vs. 255 days in the IC group 
(P=0.04; HR 1.34, 95% CI 1.01-1.79). 1-year survival was 28% vs. 
35%. CR was reported in 7 (EC) vs. 18 (IC) patients (P=0.02). There 
were no signiﬁcant differences with respect to haematological grade 
III-IV toxicity, and no severe diarrhea was observed. Minor group dif-
ferences were seen with regard to patient reported symptom palliation 
(i.e. sleep disturbance and dyspnea) and hair loss in favour of the IC 
group, while functioning and global QoL ratings over time were similar 
in both groups.
Conclusion: Irinotecan+carboplatin is superior to oral 
etoposide+carboplatin with respect to overall survival in SCLC-ED, 
without compromising QoL.
 
Patients randomized Standard dose (n=360) Higher dose (n=360) 
Baseline subjective signs  336 (93%)  339 (94%)  
on Lent-soma scale:  None Grade 1 Grade 2   None  Grade 1   Grade 2  
 - headache   79% 18% 3%  78%  18% 3% 
 - somnolence  73%  21%  5%  72% 22% 6% 
 - intellectual deficit  90%  8%  1%  93% 7% 0.3% 
 - memory  81%  17%  2%  85% 15% 1% 
   -Brain CT -scan and/or MRI    93%  7%  0%  94% 6% 0% 
Patients treated with PCI    
n=355 
Conventional 
n=277 
Accelerated 
hyperfrac. n=79 
Immediate Toxicity:   171 (48%)  147 (53%)  32 (41%)  
 - headache  85 (26%)  77 (29%) 22 (29%) 
 - fatigue  101 (32%)  100 (38%) 24 (32%) 
 - insomnia  14 (4%) 12 (5%) 3 (4%)  
 - nausea/vomiting  80 (24%)  82 (31%) 19 (25%) 
 
